- Alzheimer disease (AD) is a neurodegenerative disease and the most common cause of dementia.
- There is growing recognition of individuals with cognitive impairment at a severity level insufficient for a diagnosis of dementia. Two terms have been used to describe these individuals:
- Cognitive impairment, no dementia (CIND)
- Mild cognitive impairment (MCI)
- Cortical atrophy, amyloid-predominant neuritic plaques, tau-predominant neurofibrillary tangles, and neuronal death are hallmarks of the pathological diagnosis of AD confirmed via postmortem histopathological examination.
- Cascade view of etiopathogenesis of AD:
- Genetic and environmental risk factors interact to increase the production or to decrease the clearance of a toxic form of a peptide (amyloid beta (abeta) 1-42) derived from turnover of the amyloid precursor protein (APP), a transmembrane protein present on neurons.
- If APP is processed through cleavage by β-secretase preferentially over α-secretase, this leads to the formation of abeta 1-42 that is prone to dimerization, oligomerization, and deposition in the extracellular space.
- The deposited abeta 1-42 accumulates close to the synaptic cleft and is thought to lead over time to synaptic disconnection, the loss of neurotransmitter systems, and the emergence of symptoms.
- Cognitive impairment due to AD is classified under the neurocognitive disorders (NCDs) section of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).
There's more to see -- the rest of this topic is available only to subscribers.